Annotation Detail
Information
- Associated Genes
- NRAS
- Associated Variants
-
NRAS p.Gln61Lys (p.Q61K)
(
ENST00000369535.5 )
NRAS p.Gln61Lys (p.Q61K) ( ENST00000369535.5 ) - Associated Disease
- skin melanoma
- Source Database
- CIViC Evidence
- Description
- Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1475
- Gene URL
- https://civic.genome.wustl.edu/links/genes/36
- Variant URL
- https://civic.genome.wustl.edu/links/variants/427
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Skin Melanoma
- Evidence Direction
- Supports
- Drug
- Selumetinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22194965
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Selumetinib | Sensitivity | true |